Mankind Pharma Acquires Women’s Health Portfolio from Subsidiary BSV for INR 797 Cr

The transaction, valued at ₹797 crore, will be executed on a going concern basis through a slump sale, subject to customary closing adjustments.

Mankind Pharma has entered into a Business Transfer Agreement (BTA) with its wholly owned subsidiary, Bharat Serums and Vaccines Ltd (BSV), to acquire BSV’s Branded Generic Business in the Women’s Health Rx portfolio.

The transaction, valued at ₹797 crore, will be executed on a going concern basis through a slump sale, subject to customary closing adjustments.

Under the terms of the agreement, 50% of the consideration will be paid on the closing date, while the remaining amount will be paid within 150 days.

Completion of the deal is contingent on the fulfillment of preconditions, closing actions, and other terms outlined in the agreement. Mankind had earlier disclosed details of the transaction in its July 31, 2025 filing.

Despite a dip in quarterly profit, Mankind Pharma reported a strong operational performance for Q1FY26. The company’s net profit fell 18.1% year-on-year to ₹444.6 crore from ₹543 crore in Q1FY25, while revenue from operations rose 24.5% to ₹3,570 crore.

EBITDA grew 26% to ₹847.6 crore, with margins slightly improving to 23.7% from 23.4%. Diluted EPS declined 20.1% year-on-year to ₹10.6 for the quarter.

Domestic revenue increased 18.9% to ₹3,101 crore, and export revenue rose sharply by 81.1% to ₹469 crore, driven by the consolidation of BSV and growth in the existing business.

Mankind Pharma’s market share in the Indian pharmaceutical market (IPM) improved from 4.8% in March 2025 to 4.9% in June 2025. Secondary sales for Q1FY26 grew 9.2%, surpassing the IPM growth rate of 8.6%, underscoring the company’s sustained momentum across domestic and international markets.

Stay tuned for more such updates on Digital Health News